# The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

> **NCT07232134** · PHASE3 · RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 100 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)
- Down Syndrome (DS)

## Interventions

- **DRUG:** 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).

## Key facts

- **NCT ID:** NCT07232134
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2030-07-24
- **Final completion:** 2032-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232134, "The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07232134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*